Summary

GlobalDatas pharmaceuticals report, Anyara (Renal Cell Carcinoma)- Analysis and Forecasts to 2020 provides Anyara sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Renal Cell Carcinoma market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

• Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
• Analysis and review of Anyara including historical sales data
• Qualitative and quantitative assessment of market space
• Analysis of the trends, drivers and restraints shaping and defining the markets
• In-depth analysis of Anyara including efficacy, safety, pricing, competition and other details which influence its sales potential
• Detailed sales forecast for 2013-2020 for Anyara in each of the seven major markets

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of competition by understanding the changing competitive landscape
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
• Examine the historical sales performance of a drug in seven major markets
• Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3

List of Tables

Table 1: RCC, Incidences and Mortality, 2008-2030 5
Table 2: RCC, Global, Market Size Forecast ($bn), 20092020 8
Table 3: Drug Risk Benefit Score of ANYARA 15
Table 4: Efficacy and Safety Comparison of ANYARA with its Competitors 16
Table 5: Renal Cancer, Global, Estimated Sales of ANYARA ($m), 20132020 18
Table 6: Renal Cancer, The US, Estimated Sales of ANYARA ($m), 20132020 19
Table 7: Renal Cancer, The UK, Estimated Sales of ANYARA ($m), 20132020 20
Table 8: Renal Cancer, France, Estimated Sales of ANYARA ($m), 20132020 21
Table 9: Renal Cancer, Germany, Estimated Sales of ANYARA ($m), 20132020 21
Table 10: Renal Cancer, Italy, Estimated Sales of ANYARA ($m), 20132020 22
Table 11: Renal Cancer, Spain, Estimated Sales of ANYARA ($m), 20132020 22
Table 12: Renal Cancer, Japan, Estimated Sales of ANYARA ($m), 20132020 23

List of Figures

Figure 1: Percentage Distribution of Top 20 Diagnosed Cancers 4
Figure 2: % Difference of Incidence and Mortality of Top 20 Cancers 5
Figure 3: Per Capita Cigarette Consumption , The US, 1976-2006 6
Figure 4: RCC, Global, Market Size Forecast ($bn), 20092020 8
Figure 5: Oncology, Global, Estimated Incidence 2008-2030 9
Figure 6: RCC, Global, Estimated Incidence 2008-2030 9
Figure 7: Broad Classification of Kidney Cancer 11
Figure 8: Detailed TNM Classification 12
Figure 9: Classification of RCC (The US, EU except The UK and Japan) 12
Figure 10: Classification of RCC (The UK) 13
Figure 11: Drug Model Diagram of ANYARA in the US, EU (except UK) and Japan 17
Figure 12: Drug Model Diagram of ANYARA in the UK 17
Figure 13: Renal Cancer, Global , Estimated Sales of ANYARA($m) , 20132020 18
Figure 14: Renal Cancer, Global, Sales Distribution, 2020 19
Figure 15: Renal Cancer, The US , Estimated Sales of ANYARA($m) , 20132020 19
Figure 16: Renal Cancer, The UK , Estimated Sales of ANYARA($m) , 20132020 20
Figure 17: Renal Cancer, France , Estimated Sales of ANYARA($m) , 20132020 20
Figure 18: Renal Cancer, Germany , Estimated Sales of ANYARA($m) , 20132020 21
Figure 19: Renal Cancer, Italy , Estimated Sales of ANYARA($m) , 20132020 21
Figure 20: Renal Cancer, Spain , Estimated Sales of ANYARA($m) , 20132020 22
Figure 21: Renal Cancer, Japan , Estimated Sales of ANYARA($m) , 20132020 23
Figure 22: GlobalData Methodology 24
Figure 23: Drug Model Diagram 26
Figure 24: Patients Approved for the Drug 26